Molecular aspects of breast cancer resistance to drugs (Review)

Simple item page
datacite.alternateIdentifier.citationINTERNATIONAL JOURNAL OF ONCOLOGY,Vol.47,437-445,2015
datacite.alternateIdentifier.doi10.3892/ijo.2015.3055
datacite.creatorCalaf, Gloria M.
datacite.creatorZepeda, Andrea B.
datacite.creatorCastillo, Rodrigo L.
datacite.creatorFigueroa, Carolina A.
datacite.creatorArias, Consuelo
datacite.creatorFigueroa Villalobos, Elías
datacite.creatorFarias, Jorge G.
datacite.date2015
datacite.subject.englishbreast cancer
datacite.subject.englishmultidrug resistance
datacite.subject.englishcancer classifications
datacite.titleMolecular aspects of breast cancer resistance to drugs (Review)
dc.date.accessioned2021-04-30T17:05:04Z
dc.date.available2021-04-30T17:05:04Z
dc.description.abstractDespite continuous advances in the knowledge of breast cancer pathophysiology, this type of neoplasia remains a leading cause of cancer-related death in women worldwide. Carcinogenesis takes a progressive course from somatic mutations, alteration of the DNA repair mechanisms, inhibition of growth suppressors, followed by cell proliferation, tissue invasion and risk of metastasis. Less than 10% of all cancers are hereditary, and in the case of breast cancer only 8%, a phenomenon linked to genetic changes in BRCA1 or BRCA2. All the other cancers can be caused by an infection (15%) or in most cases (75%) the etiology is unknown. Patients with genetic mutations in BRCA1 or BRCA2 have 30-60% likelihood of developing a second primary breast cancer and between 11 and 45% risk of ovarian cancer, HER-2/neu is overexpressed in similar to 30% of human breast tumors and it has a predictive role in chemotherapy and endocrine therapy.
dc.identifier.urihttp://repositoriodigital.uct.cl/handle/10925/3924
dc.language.isoen
dc.publisherSPANDIDOS PUBL LTD
dc.sourceINTERNATIONAL JOURNAL OF ONCOLOGY
oaire.resourceTypeArticle
uct.catalogadorWOS
uct.indizacionSCI
Files
Collections
Migración Web of Science